Xeris Biopharma Holdings (XERS) Non-Current Debt (2023 - 2025)
Historic Non-Current Debt for Xeris Biopharma Holdings (XERS) over the last 3 years, with Q3 2025 value amounting to $219.5 million.
- Xeris Biopharma Holdings' Non-Current Debt changed N/A to $219.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $219.5 million, marking a year-over-year change of. This contributed to the annual value of $217.0 million for FY2024, which is 1365.62% up from last year.
- Xeris Biopharma Holdings' Non-Current Debt amounted to $219.5 million in Q3 2025.
- Over the past 5 years, Xeris Biopharma Holdings' Non-Current Debt peaked at $219.5 million during Q3 2025, and registered a low of $190.9 million during Q4 2023.
- In the last 3 years, Xeris Biopharma Holdings' Non-Current Debt had a median value of $217.8 million in 2025 and averaged $212.8 million.
- Examining YoY changes over the last 5 years, Xeris Biopharma Holdings' Non-Current Debt showed a top increase of 1365.62% in 2024 and a maximum decrease of 1365.62% in 2024.
- Over the past 3 years, Xeris Biopharma Holdings' Non-Current Debt (Quarter) stood at $190.9 million in 2023, then rose by 13.66% to $217.0 million in 2024, then rose by 1.13% to $219.5 million in 2025.
- Its Non-Current Debt stands at $219.5 million for Q3 2025, versus $218.6 million for Q2 2025 and $217.8 million for Q1 2025.